How can real stories, ethical insights, and a 3-phase approach reshape how we view medical breakthroughs? ??????? Join Dr. Mace Rothenberg and Derk Arts, MD PhD on March 27th to ? Delve into the backstory that inspired the Museum of Medicine and Biomedical Discovery ? Learn how engaging exhibits tackle real-world problems ? Find out why now is the perfect time to bridge research and community dialogue Sign up here: https://lnkd.in/eXiME3gy
Castor
软件开发
New York,NY 21,837 位关注者
Delightful for patients, effortless for study teams, risk-free for sponsors.
关于我们
At Castor, we believe in the power of clinical research and the power of technology. And we know that together, these forces can help extend human healthspan. To achieve this reality, we must make patient-centered clinical trials a possibility for everyone, anywhere in the world. That's why we are using technology to capture the world's research data and optimize each activity of a clinical trial. From recruitment to monitoring, our modular clinical trial platform makes it easier to design and deploy trials, enroll and engage patients, collect data and analyze results. Each module can be used individually or in unison with others, providing the ability to customize each solution to fit your needs, and grow at your own pace. That’s delightful for patients, effortless for study teams, risk-free for sponsors.
- 网站
-
https://www.castoredc.com
Castor的外部链接
- 所属行业
- 软件开发
- 规模
- 201-500 人
- 总部
- New York,NY
- 类型
- 私人持股
- 创立
- 2011
- 领域
- Electronic Data Capture、Healthcare IT、SaaS、Medical Research、eCRF、ePRO、CDMS、clinical trial management、FHIR、FAIRdata、health IT、FAIR data、EDC、clinical trial data、medical device data、eConsent、eCOA、Decentralized trials、Remote clinical trials、RWE和Real-World Evidence
地点
Castor员工
动态
-
?? Most RCTs fail to capture what happens in messy clinical practice. Phase IV data exposes this gap. ?? Phase IV trials are NOT optional extras - they're where the REAL truth emerges. Here's some food for thought... Pre-approval trials are too small, too homogeneous, and too controlled to predict real outcomes. Phase IV surveillance reveals: AEs that emerge only at population scale Treatment failures in specific genetic/demographic subgroups Off-label uses that outperform approved indications ?? EHR integration alone won't solve the bias problem. We need better Phase IV methodologies, not just bigger datasets. https://lnkd.in/e4FA-BET #RWE #PostMarketSafety #ClinicalMethodology
-
-
Castor转发了
?? ?? Let's plant some trees and find Castor's next talent!?? ?? For every candidate tagged by you in the comments on this LinkedIn post, Castor will plant one tree - up to 1,500 trees total! And there's more: if your referral gets hired, you can choose between a $2,000?? referral bonus OR having a coral tree planted in your name in the ocean near Bonaire (see picture, your name tag will be there under water). ?? ?? We're actively seeking: ?? Life Science Sales champions ?? Project Managers ??? Engineers If you had any doubt about why Castor is a fit: ?? We support over 15.000 studies globally that help increase human health. ?? Our impact program enables 100s over studies in underserved disease areas, like neglected tropical diseases and women's health. ?? All roles are fully remote. ?? We have an (uncurated) 4.2 ? rating on Glassdoor. Let's make the world a bit greener and find someone a new job!
-
-
At Castor, integrity and honesty guide our commitment to protecting patient, sponsor, and client data—because we see security not as a checkbox, but as part of a culture of quality and trust. That’s why we’re very proud of our Chief Information Security Officer, Gijs Roeffen, for his expert contribution in Hunt & Hackett’s 2025 Cybersecurity Trend Report! Gijs’s forward-thinking insights on the evolving threat landscape echo the same values we uphold at Castor: from proactive measures like secure code reviews and zero-trust network practices, to transparent protocols for compliance with ISO 27001 and beyond. Every layer of our platform—application-level encryption, multi-factor authentication, immutable audit logs—reflects the rigor we bring to clinical research. Here’s to building a safer, more innovative future in clinical research—together.
-
-
“Paper disguised as digital” consent misses a big opportunity. Instead, think of eConsent as a curated experience. Add short educational videos, simple quizzes, and quick feedback loops. Sponsors gain long-term savings when retention improves. Sites appreciate efficient, time-saving processes. Participants finally get the clarity they crave. ????? The path forward combines ethical responsibility with real-world feasibility. Read more from Derk on this topic > https://lnkd.in/ePYYWYXB
-
-
Curious about the hidden stories behind every medical breakthrough? Tune in on March 27, as Dr. Mace Rothenberg and Derk discuss how mistakes, ethics, and bioengineering fuel innovation—and why a museum is the perfect place to explore it all. ?????? ? Hear about the 3-phase roadmap for bringing medical history to life through the Museum of Medicine and Biomedical Discovery ? Discover new ways to engage beyond academia and industry ? Take away fresh ideas for connecting science with real people
Science’s Past and Future: Why a Life Sciences Museum Matters
www.dhirubhai.net
-
Kidney disease hits 850 million people. By 2040, CKD is expected to become the 5th leading cause of years of life lost, reminding us just how important early detection and continuous research truly are. At Castor, we refuse to settle for weak data in nephrology trials. Better data leads to sharper insights and stronger treatments. No researcher should accept blind spots. No patient should suffer because of lazy testing or scattered information. ?????? On World Kidney Day, push for swift detection, targeted care, and real results. The science exists—we just need to use it. Let’s break down data silos and empower clinicians to tackle CKD head-on. #WorldKidneyDay #KidneyHealth #ClinicalResearch #CKD #BetterDataBetterTreatments #HealthcareInnovation
-
Too many teams assume they should build tech in-house—until they’re drowning in scope creep, tech debt, and spiraling costs. Ask yourself this before you build: ?? Is this truly a competitive advantage—or just a project for the sake of it? ??? Do you have the internal resources to maintain and update it for years? ?? Will it still be viable in 5 years—or will industry shifts make it obsolete? As Nick Darwall-Smith put it: “One of the biggest pitfalls with internal development is not taking the full scope into consideration. What starts as a simple solution can become a long-term maintenance burden.” In this article, Derk and Nick Darwall-Smith break down the costly mistakes and smart strategies for life sciences tech decisions. ?? Read it here: https://lnkd.in/ejYKCbah
-
-
On #IWD2025, we celebrate the amazing women at Castor and beyond. ?? We believe ignoring women’s health is like driving with one headlight off—reckless. This special issue of Science Advances highlights some of the most exciting areas of discovery in women’s health science (https://lnkd.in/evT5vnPU). From the complex interplay between menopause and Alzheimer’s risk to the role of hormonal targets like Kir7.1 in uteroplacental function, these studies illustrate the biological nuances of sex-based health. It’s our opinion postpartum depression, endometriosis, PCOS, and more deserve urgent focus. ?????? We believe #AccelerateAction is the only way forward. Explore these resources: ? Gates Foundation: https://lnkd.in/ex2kbrzf ? Wellcome Trust: https://lnkd.in/eQAqEfNp ? Castor’s Impact Program: https://lnkd.in/eSXhUw8y ? MSD: https://lnkd.in/e6e9MWXq ? NIH: https://lnkd.in/erW9NPeN #ForAllWomenAndGirls #InternationalWomensDay
-
-
?? Key panel alert ?? Our own Derk Arts, takes to the #SOS2025 stage next week alongside key industry voices on the topic of AI in clinical research. Don't miss this one!
?? SOS 2025 Panel Drop! ???? Next up—the session that everyone’s been asking for! If requests, comments, and feedback could turn into currency, this panel would be a Fortune 500 company. ???? Session 2: AI, DCT, and the Future of Trials: Adapting, Innovating, Excelling The clinical research landscape is shifting fast. AI is here. DCT is evolving. Trials are changing. The question is—are you ready to adapt and lead? ?? Andrew Mitchell Mike Wenger Haley Dougay Bo Lora Derk Arts, MD PhD This isn’t a future conversation—it’s happening now. Be in the room where the industry shifts. ?? Stay tuned as we roll out more incredible speakers who will be tackling the biggest challenges, innovations, and solutions in clinical research. ?? Join us at SOS 2025 & tag someone who NEEDS to be in this session! ?? #SOS2025 #SaveOurSites #ClinicalResearch #ConferenceSpeakers #IndustryLeaders #LetsGo Dan Sfera